Type 2 Diabetes

Implications for treating patients at risk of cardiovascular disease with rivaroxaban plus aspirin based on the COMPASS and VOYAGER PAD clinical trials.

Comparing data from patients with primary nephrotic syndrome to matched controls in a 1:100 ratio, investigators found these patients were at a 19-fold greater risk of end-stage kidney disease and a 3-fold greater risk of acute coronary syndrome events.

New research from the Joslin Diabetes Center details the impact of comorbidities on quality of life in patients with type 1 diabetes.

Improvements in neovascularization and best-correct visual acuity were generally not sustained following treatment discontinuance.

A multidisciplinary panel of experts shares insights into identifying symptoms of hypoglycemia and highlights the importance of stratifying level 1, 2, and 3 blood glucose levels when making the differential diagnosis in diabetes.

Expert panelists provide an overview of health complications associated with mild and severe hypoglycemic episodes and emphasize the importance of patient awareness and early recognition to improve quality of life and health-related outcomes.

Recommendations for treating patients with coronary artery disease and type 2 diabetes with dual antiplatelet therapy based on data revealed by the THEMIS trial.

Strategies used to help determine patients’ risk for cardiovascular disease and the role of lifestyle management in helping reduce the risk for events in patients with type 2 diabetes.

Data from the UK Biobank cohort details the increased risk of adverse health outcomes, including the development of diabetes and heart failure, among patients considered to have metabolically healthy obesity.

A systematic review details the impact of topical agents for the treatment of diabetes-related ophthalmic conditions, such as diabetic macular edema and diabetic retinopathy.

A comparison of women with PCOS to matched controls indicates women with PCOS were at a 26% greater risk of experiencing major adverse cardiovascular events than their counterparts without polycystic ovary syndrome.

Reported HRQOL remains consistent in youth with T1D, but multiple comorbidities and mental health conditions linked to decline.

Dapagliflozin and the SGLT2 inhibitor class may have untapped potential far beyond the reduction of heart failure hospitalization risk.

A cross-sectional analysis of NHANES data paints a grim picture related to rates of patients with diabetes achieving goals for glycemic, blood pressure, and lipid control.

A systematic review of clinical trials notes that topical eye drops may lead to favorable retinal and visual outcomes, despite heterogeneity across multiple studies.

An expert discussion on the recent FDA committee decision to support teplizumab in delaying clinical type 1 diabetes.

An analysis of data from nearly 500k patients suggests patients with diabetes experiencing frequent insomnia were at an 87% increased risk of all-cause mortality compared to those with neither sleep disturbances nor diabetes.

Thought leaders in diabetes provide closing remarks about the importance of continuous awareness of glycemic control in patients as well as the need for effective communication between patients and providers. 

A panel of experts in the treatment of diabetes discusses the importance of self-management of blood glucose levels and emphasizes the need for multidisciplinary care teams and referrals for optimal disease management.

Thought leaders in diabetes discuss challenges of insurance coverage for new formulations of glucagon and comment on the potential for long-term cost savings due to decreased overall healthcare system utilization.

Experts in endocrinology build a discussion on new intranasal and injectable formulations of glucagon and discuss their benefits compared to glucagon kits that require reconstitution.

Key thought leaders in endocrinology review different signs and symptoms of hypoglycemia across vulnerable patient populations and discuss factors that may impact the pharmacologic management of blood glucose levels.

A panel of thought leaders in the management of diabetes reviews the mainstays of treatment for hypoglycemic episodes and builds a discussion on effective non-pharmacologic strategies for raising blood glucose levels.

Key opinion leaders in diabetes comment on various blood glucose tests to assess hypoglycemia and prevent future episodes.

A multidisciplinary panel of experts shares insights into identifying symptoms of hypoglycemia and highlights the importance of stratifying level 1, 2, and 3 blood glucose levels when making the differential diagnosis in diabetes.

Expert panelists provide an overview of health complications associated with mild and severe hypoglycemic episodes and emphasize the importance of patient awareness and early recognition to improve quality of life and health-related outcomes.

A panel of experts in diabetes builds a discussion on hypoglycemia and shares key insights into its impact on community health by considering overall challenges of glucose management.

A panel of experts in diabetes builds a discussion on hypoglycemia and shares key insights into its impact on community health by considering overall challenges of glucose management.

Our latest case report from Dr. Brady Pregerson features a man in his 30s presenting to the ED after drinking and admits to forgetting his insulin and poor adherence to other antidiabetes medication. Can you determine the correct diagnosis?

An analysis of food frequency questionnaire and biomarker data from more than 7000 adults indicates consumption of 2 or more servings of whole fruit per day was associated with 36% lower odds of developing diabetes in the next half-decade.